Medical News Feed
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | 5HT1 -agonists. |
| Generic Name : | Rizatriptan |
| Drug description : | Maxalt: 5 mg pink capsule-shaped tablet marked MSD and 266; 10 mg pink capsule-shaped tablet marked MAXALT and MSD 267. Maxalt Melt: 10 mg white, round, peppermint flavoured oral lyophilisate embossed with rounded square. |
| Presentation : | Maxalt: tablets, rizatriptan (as benzoate salt) 5mg , 10mg . Maxalt Melt: wafers, 10mg . |
| Indications : | Acute treatment of headache phase of migraine with or without aura. |
| Adult Dosage : | 10 mg swallowed whole with liquid or water dissolved on the tongue. Repeat if necessary after at least two hours. Maximum two doses in 24 hours. |
| Child Dosage : | Under 18 years, not recommended. |
| Contra Indications : | Hypersensitivity to rizatriptan or any of the ingredients. Concurrent administration of MAOIs or use within two weeks of discontinuation of MAOI. Severe hepatic or severe renal insufficiency. Previous CVA or TIA. Moderately severe or severe hypertension, or untreated mild hypertension. Established coronary artery disease, including ischaemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischaemia), signs and symptoms of ischaemic heart disease, or Prinzmetal's angina. Peripheral vascular disease. Concomitant use of rizatriptan and ergotamine, ergot derivatives (including methysergide), or other 5-HT receptor agonists. 1B/1D |
| Special Precautions : | Elderly. Moderate/mild renal or hepatic insufficiency, Phenylketonuria with Maxalt Melt (contains aspartame). Pregnancy, lactation. Evaluate coronary artery disease (CAD) and ischaemic heart disease (IHD). Maxalt should not be given to patients with established CAD. |
| Interactions : | MAOIs, ergotamine, ergot derivatives, other 5HT receptor agonists, propranalol, drugs 1 acting as cytochrome P450 CYP2D6 substrates, beta-blockers. |
| Adverse Reactions : | Dizziness, somnolence, asthenia, abdominal or chest pain, palpitations, tachycardia, GI CNS disturbances, pharyngeal discomfort, dyspnoea, skin reactions, blurred vision, hot flushes, tongue swelling, rash, dysgeusia/bad taste. Very rarely, myocardial ischaemia or infarction, cerebrovascular accident. |
| Manufacturer : | MSD |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org